GPX4 and gastric cancer: Cisplatin-based chemotherapy remains the primary treatment for advanced gastric cancer, however, chemotherapy resistance remains a significant challenge to clinical efficacy.194,195 Dysregulation of the Wnt/β-catenin pathway is closely linked to the development of gastric cancer and the emergence of chemotherapy resistance.196 When the Wnt/β-catenin pathway is activated, it can reduce lipid ROS production in gastric cancer cells, and the β-catenin/TCF4 transcription complex can directly bind to the GPX4 promoter region, enhancing its expression and thereby inhibiting cell ferroptosis.